EQUITY RESEARCH - COMPANY REPORT



THAILAND / SERVICES



We cut our 2024E profit by 15% to price in a lower-than-expected 2Q24 profit due to higher expenses and lower-than-expected profit sharing from associates.

Believe profit has bottomed in 2Q24

- However, 2Q24 could be this year's trough, and the profit may recover sharply from 3Q24 onwards.
- MASTER has tumbled to reflect the below-estimate profit.

2Q24 profit missed estimates

MASTER reported a2Q24 net profit of THB88m (-17.6% q-q, +7.5% y-y). Excluding one-time consultancy fees of THB9m, the core profit equaled THB97m (-9% q-q, +18.5% y-y) due to higher expenses and lower profitsharing from associates. The revenue and gross margin of hospitals under Master were healthy, with in-line revenue growth of 9% q-q and 11% y-y. Although the utilization rate of its operating rooms was flat q-q at 60%, it was due to revenue from Men Health, which excludes the use of operating rooms. Meanwhile, the gross margin stood at 57%, down from 58.5% in 1Q24 due to a change in the revenue mix but still up from 55.5% in 2Q23.

Higher expenses and lower-than-expected profit sharing from associates

Expenses surged 17% q-q and 19% y-y, driving SG&A to sales to 36.9%, up from 34.3% in 1Q24 and 2Q23 due to higher personnel and depreciation expenses. Profit sharing from associates decreased to THB7m from THB10m in 1Q24. Although MASTER started to realize V square, it contributed a slight loss of THB0.4m due to new accounting standards, particularly TFRS16 (lease). Also, it was investing in tools and equipment. Meanwhile, Wind Clinic contributed a higher loss of THB3m from THB0.3m in 1Q24 since it started providing surgery services using an external operating room, resulting in high

Believe profit has troughed in 2Q24 and expect sharp recovery from 3Q24 onwards

MASTER maintained its 2024 revenue growth target of no less than 20% y-y. Initially, we believe the profit has seen its trough in 2Q24 and expect 2H24 profit to accelerate to its normalized level, supported by (1) a high season for surgery, (2) IPD revenue realization (after IPD beds increase from 15 to 19), and (3) an expected rise in the quarterly profit sharing from associates to THB12-15m in 2H24 due to V Square, which should turn profitable from 3Q24 onward. Also, we expect other associates to recover and report a higher

Slash 2024E profit, but the share price has already been priced in

Given the below-estimate 2Q24 profit, we cut our 2024E net profit by 15% to THB525m (+26% y-y), leading to a TP cut to THB52 (from THB72) to incorporate a lower growth rate and a lower PE target of 30x (from 35x). However, MASTER has plunged 36% in the past three months to factor in the disappointing 2Q24 profit. Hence, we retain our BUY rating to capture robust recoveries from 3Q24 onwards.



UNCHANGED

TARGET PRICE	THB52.00
CLOSE	THB40.75
UP/DOWNSIDE	+27.6%
PRIOR TP	THB72.00
CHANGE IN TP	-27.8%
TP vs CONSENSUS	-26.2%

KEY STOCK DATA

YE Dec (THB m)	2023	2024E	2025E	2026E
Revenue	1,917	2,249	2,472	2,766
Net profit	416	525	611	705
EPS (THB)	1.58	1.74	2.03	2.34
vs Consensus (%)	-	(6.7)	(5.7)	(9.2)
EBITDA	586	682	776	876
Recurring net profit	416	525	611	705
Core EPS (THB)	1.58	1.74	2.03	2.34
Chg. In EPS est. (%)	-	(15.4)	(10.8)	(7.6)
EPS growth (%)	(2.2)	10.4	16.4	15.3
Core P/E (x)	25.8	23.4	20.1	17.4
Dividend yield (%)	0.7	1.3	2.0	2.3
EV/EBITDA (x)	17.8	18.0	15.6	13.5
Price/book (x)	3.6	3.6	3.3	2.9
Net debt/Equity (%)	(11.1)	(1.4)	(5.8)	(12.2)
ROE (%)	24.5	16.5	17.1	17.7



Share price performance	1 Month	3 Month	12 Month
Absolute (%)	(33.2)	(29.4)	(28.6)
Relative to country (%)	(31.2)	(25.0)	(15.8)
Mkt cap (USD m)			352
3m avg. daily turnover (USD m)			3.1
Free float (%)			0
Major shareholder	Mascl	namadol fa	mily (68%)
12m high/low (THB)		7-	4.00/36.31
Issued shares (m)			301.71

Sources: Bloomberg consensus; FSSIA estimates



Sureeporn Teewasuwet

Fundamental Investment Analyst on Securities; License no. 040694 sureeporn.t@fssia.com, +66 2646 9972

Investment thesis

We expect Thailand's cosmetic surgery market to grow by 9.7% CAGR in 2023-30, close to global cosmetic surgery markets. Additionally, the medical tourism trend should support surgery hospitals in Thailand to have a higher revenue mix from international customers, which would in turn support future growth.

MASTER has several strengths. It has earned a good reputation and has become well-known over the past ten years. Given the experience of Dr. Raweewat Maschamadol and other renowned doctors, MASTER has gained customer trust, leading to referrals and positive reviews on social media. It has also expanded and invested in other businesses to further its long-term growth.


Company profile

MASTER is in the cosmetic surgery hospital business under Masterpiece Hospital. Established in 2012, it has 17 operating beds and offers one-stop cosmetic surgery services. MASTER earns revenue from four services, including surgery, skin, hair treatment, and aftercare, with surgery contributing the highest revenue of 81% of total revenue.

www.masterpiecehospital.com

Principal activities (revenue, 2023)

- Surgery 81.0 %
- Skin 7.1 %
- Hair treatment 6.0 %
- Aftercare 3.6 %
- Others 2.3 %




Source: Master Style

Major shareholders

■ Maschamadol family - 68.0 %

■ Others - 32.0 %



Source: Master Style

Catalysts

2024 potential growth drivers include 1) more surgery customers; 2) a higher utilization rate for operating beds, which would drive operating leverage; and 3) the realization of profit and synergies from M&As.

Risks to our call

Downside risks to our P/E-based TP include 1) increased competition; 2) a pandemic that results in a lockdown; 3) lower-than-expected utilization rate of new operating beds; 4) higher-than-expected doctor costs and expenses; and 5) a loss contribution from the acquired units.

Event calendar

Date	Event
November 2024	3Q24 results announcement

Key assumptions

	2024E	2025E	2026E
Total OR room (no.)	17	17	17
Capacity hours (hours)	77,563	77,563	77,563
Operating hours (hours)	55,845	58,172	62,050
Utilisation rate (%)	72.0	75.0	80.0

Source: FSSIA estimates

Earnings sensitivity

- For every 5% increase in revenue, we estimate 2024 net profit to rise by 3.9%, and vice versa, all else being equal.
- For every 0.5% increase in GPM, we estimate 2024 net profit to rise by 2%, and vice versa, all else being equal.
- For every 1% increase in SG&A, we estimate 2024 net profit to fall by 3.5%, and vice versa, all else being equal.


Source: FSSIA estimates

Exhibit 1: MASTER – 2Q24 earnings results

	1Q23	2Q23	3Q23	4Q23	1Q24	2Q24	Cha	inge	1H23	1H24	Change
	(THB m)	(q-q%)	(y-y%)	(THB m)	(THB m)	(y-y%)					
Sales	436	459	479	543	468	510	9.0	11.1	895	978	9.3
Cost of sales	182	204	200	198	194	220	13.1	7.4	387	414	7.0
Gross profit	253	255	279	345	274	291	6.1	14.1	508	564	11.1
SG&A	162	158	160	154	160	188	17.3	19.4	320	348	8.9
Operating profit	94	106	128	197	122	108	(11.5)	2.4	199	231	15.7
Profit sharing	0	0	0	5	10	7	(34.0)	nm	0	17	nn
Interest expense	3	4	4	3	3	3	(0.0)	(3.5)	7	7	(3.2)
Tax expense	19	21	25	40	23	18	(24.0)	(14.4)	39	41	4.9
Reported net profit	72	81	100	164	106	88	(17.6)	7.5	153	194	26.6
Core profit	72	81	100	164	106	97	(9.1)	18.5	153	203	32.5
Key Ratios (%)							(ppt)	(ppt)			
Gross margin	58.2	55.5	58.2	63.6	58.5	57.0	(1.6)	1.5	56.8	57.7	0.9
SG&A to sales	37.2	34.3	33.5	28.3	34.3	36.9	2.6	2.6	35.7	35.6	(0.1,
Operating margin	21.5	23.1	26.8	36.3	26.2	21.2	(4.9)	(1.8)	22.3	23.6	1.3
Net margin	16.4	17.7	20.8	30.1	22.7	17.2	(5.5)	(0.6)	17.1	19.8	2.7
Core margin	16.4	17.7	20.8	30.1	22.7	18.9	(3.8)	1.2	17.1	20.7	3.6
Operating Statistics											
Total OR rooms (no.)	7	7	17	17	17	17			17	17	
Operating hours (hours)	10,752	11,975	12,587	14,316	11,386	11,564	1.6	(3.4)	22,727	22,950	1.0
Utilization rate (%)	94.8	81.3	64.9	73.8	60.1	60.3			88.1	62.6	
Revenue breakdown (THB m)											
Surgery	340	364	387	462	375	416	10.8	14.4	20.5	12.7	53.0
Skin	42	34	33	27	27	26	(3.0)	(24.6)	16.6	(10.2)	(17.9)
Hair treatment	28	32	31	24	27	37	35.2	15.5	20.5	33.5	171.8
Aftercare	18	18	17	17	29	22	(22.3)	22.2	37.8	363.4	(59.0
Other	8	11	11	13	11	9	(10.4)	(15.8)	23.0	359.2	(45.2)
Revenue proportion (%)											
Surgery	78.0	79.2	80.8	85.1	80.2	81.5	1.4	2.3	(81.0)	(81.6)	(0.6
Skin	9.6	7.5	6.8	5.0	5.7	5.1	(0.6)	(2.4)	(7.1)	(7.1)	(0.1)
Hair treatment	6.4	6.9	6.5	4.4	5.8	7.2	1.4	0.3	(6.0)	(5.9)	0.
Aftercare	4.1	3.9	3.5	3.2	6.1	4.3	(1.7)	0.4	(3.6)	(3.4)	0.3
Other	1.9	2.4	2.4	2.3	2.2	1.8	(0.4)	(0.6)	(2.3)	(2.0)	0.2


 $Sources: MASTER, \, FSSIA' \, compilation$

Exhibit 2: Operating hours and utilisation rate



Sources: MASTER, FSSIA' compilation

Exhibit 3: Quarterly net profit




Sources: MASTER, FSSIA' compilation

Exhibit 4: Changes in key assumptions for MASTER

		Current			Previous			Change		
	2024E	2024E 2025E 2026E		2024E	2025E	2026E	2024E 2025E 2026E			
	(THB m)	(THB m)	(THB m)	(THB m)	(THB m)	(THB m)	(%)	(%)	(%)	
Total revenue	2,249	2,472	2,766	2,326	2,556	2,861	(3.3)	(3.3)	(3.3)	
Costs	922	1,004	1,120	949	1,038	1,159	(2.8)	(3.3)	(3.3)	
Gross profit	1,327	1,468	1,646	1,377	1,518	1,702	(3.6)	(3.3)	(3.3)	
SG&A expense	753	816	913	768	844	944	(1.8)	(3.3)	(3.3)	
Interest expense	15	15	15	15	15	15	0.0	0.0	0.0	
Profit sharing	45	70	100	125	137	144	(64.0)	(48.9)	(30.6	
Reported net profit	525	611	705	621	685	763	(15.4)	(10.8)	(7.6	
Core profit	525	611	705	621	685	763	(15.4)	(10.8)	(7.6)	
Key ratios (%)										
Total revenue growth	17.3	9.9	11.9	21.4	9.9	11.9				
Net profit growth	26.2	16.4	15.3	49.2	10.3	11.3				
Core profit growth	26.2	16.4	15.3	49.2	10.3	11.3				
Gross margin	59.0	59.4	59.5	59.2	59.4	59.5	(0.2)	0.0	0.0	
SG&A to sales	33.5	33.0	33.0	33.0	33.0	33.0	0.5	0.0	0.	
Net margin	23.4	24.7	25.5	26.7	26.8	26.7	(3.4)	(2.1)	(1.2	
Core margin	23.4	24.7	25.5	26.7	26.8	26.7	(3.4)	(2.1)	(1.2	
Profit sharing to net profit	8.6	11.5	14.2	20.1	20.0	18.9	(11.6)	(8.5)	(4.7	
Operating statistics										
Total OR room (no.)	17	17	17	17	17	17	0.0	0.0	0.0	
Capacity hours (hours)	77,563	77,563	77,563	80,665	80,665	80,665	(3.8)	(3.8)	(3.8	
Operating hours (hours)	55,845	58,172	62,050	58,079	60,499	64,532	(3.8)	(3.8)	(3.8	
Utilisation rate (%)	72.0	75.0	80.0	72.0	75.0	80.0	0.0	0.0	0.0	
Revenue breakdown (THB m)										
Surgery	1,835	2,007	2,247	1,908	2,087	2,337	(3.8)	(3.8)	(3.8	
Skin	161	185	210	161	185	210	0.0	0.0	0.0	
Hair treatment	133	150	170	136	154	175	(2.6)	(2.6)	(2.6	
Aftercare	75	82	88	75	82	88	0.0	0.0	0.	
Other	46	48	50	46	48	50	0.0	0.0	0.	
Revenue proportion (%)										
Surgery	81.6	81.2	81.2	82.0	81.6	81.7				
Skin	7.1	7.5	7.6	6.9	7.2	7.3				
Hair treatment	5.9	6.1	6.2	5.9	6.0	6.1				
Aftercare	3.4	3.3	3.2	3.2	3.2	3.1				
Other	2.0	1.9	1.8	2.0	1.9	1.8				


Source: FSSIA estimates

Exhibit 5: Yearly operating hours and utilisation rate




Sources: MASTER; FSSIA estimates

Exhibit 7: Total revenue and growth




Sources: MASTER; FSSIA estimates

Exhibit 9: Profit sharing and % to net profit




Sources: MASTER; FSSIA estimates

Exhibit 6: Revenue breakdown by type of service




Sources: MASTER; FSSIA estimates

Exhibit 8: Gross margin and SG&A



Sources: MASTER; FSSIA estimates

Exhibit 10: Net profit and growth



Sources: MASTER; FSSIA estimates

Financial Statements

Master Style

Profit and Loss (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Revenue	1,483	1,917	2,249	2,472	2,766
Cost of goods sold	(641)	(785)	(922)	(1,004)	(1,120)
Gross profit	841	1,132	1,327	1,468	1,646
Other operating income	8	27	31	32	36
Operating costs	(463)	(634)	(753)	(816)	(913)
Operating EBITDA	422	586	682	776	876
Depreciation	(35)	(62)	(77)	(92)	(107)
Goodwill amortisation	0	0	0	0	0
Operating EBIT	386	525	605	685	769
Net financing costs	(4)	(9)	(9)	(9)	(9)
Associates	0	5	45	70	100
Recurring non-operating income	0	5	45	70	100
Non-recurring items	0	0	0	0	0
Profit before tax	383	521	641	745	860
Tax	(76)	(105)	(115)	(134)	(155)
Profit after tax	306	416	525	611	705
Minority interests	-	-	-	-	-
Preferred dividends	-	-	-	-	-
Other items	-	-	-	-	-
Reported net profit	306	416	525	611	705
Non-recurring items & goodwill (net)	0	0	0	0	0
Recurring net profit	306	416	525	611	705
Per share (THB)					
Recurring EPS *	1.61	1.58	1.74	2.03	2.34
Reported EPS	1.61	1.58	1.74	2.03	2.34
DPS	0.30	0.27	0.52	0.81	0.93
Diluted shares (used to calculate per share data)	190	264	302	302	302
Growth					
Revenue (%)	124.8	29.3	17.3	9.9	11.9
Operating EBITDA (%)	73.9	39.1	16.2	13.9	12.8
Operating EBIT (%)	82.7	35.9	15.3	13.2	12.3
Recurring EPS (%)	0.0	(2.2)	10.4	16.4	15.3
Reported EPS (%)	0.0	(2.2)	10.4	16.4	15.3
Operating performance					
Gross margin inc. depreciation (%)	56.7	59.1	59.0	59.4	59.5
Gross margin exc. depreciation (%)	59.1	62.3	62.4	63.1	63.4
Operating EBITDA margin (%)	28.4	30.6	30.3	31.4	31.7
Operating EBIT margin (%)	26.1	27.4	26.9	27.7	27.8
Net margin (%)	20.7	21.7	23.4	24.7	25.5
Effective tax rate (%)	19.9	20.1	18.0	18.0	18.0
Dividend payout on recurring profit (%)	18.6	17.0	30.0	40.0	40.0
Interest cover (X)	102.2	62.2	69.3	81.1	94.1
Inventory days	26.8	41.1	43.5	42.2	41.9
Debtor days	0.9	1.1	1.1	1.0	0.9
Creditor days	34.7	64.9	63.9	47.5	47.1
Operating ROIC (%)	115.1	37.7	31.2	41.6	45.3
ROIC (%)	82.1	25.8	17.3	17.5	19.2
ROE (%)	107.4	24.5	16.5	17.1	17.7
ROA (%)	40.0	18.5	14.0	14.7	15.4
* Pre-exceptional, pre-goodwill and fully diluted		. 0.0			
Revenue by Division (THB m)	2022	2023	2024E	2025E	2026E
Surgery	1,194	1,553	1,835	2,007	2,247
Skin					
	106	136	161	185 150	210
Hair treatment	90	115	133	150	170
Aftercare	62	70	75	82	88

Sources: Master Style; FSSIA estimates

Financial Statements

Master Style

Master Style					
Cash Flow (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Recurring net profit	306	416	525	611	705
Depreciation	35	62	77	92	107
Associates & minorities	0	0	0	0	0
Other non-cash items	0	(5)	(45)	(70)	(100)
Change in working capital Cash flow from operations	(100) 242	74 547	(45) 512	17 650	9 721
Capex - maintenance	-	-	-	-	-
Capex - new investment	(413)	(2,179)	(675)	(233)	(148)
Net acquisitions & disposals	-	-	-	-	-
Other investments (net)	-	-	-	-	-
Cash flow from investing	(413)	(2,179)	(675)	(233)	(148)
Dividends paid Equity finance	(263) 198	(99) 2,270	(160) 38	(244) 0	(282) 0
Debt finance	159	(11)	(2)	(2)	(2)
Other financing cash flows	(1)	2	Ó	Ó	`í
Cash flow from financing	93	2,161	(124)	(246)	(283)
Non-recurring cash flows	-	-	-	-	-
Other adjustments	0	0	0	0	0
Net other adjustments Movement in cash	(5)	0 529	0 (287)	0 171	0 290
Free cash flow to firm (FCFF)	(83) (162.06)	(1,618.40)	(267) (147.85)	431.55	587.28
Free cash flow to equity (FCFE)	(18.91)	(1,641.98)	(164.30)	415.89	571.84
	,	,	,		
Per share (THB) FCFF per share	(0.54)	(5.36)	(0.49)	1.43	1.95
FCFE per share	(0.06)	(5.44)	(0.54)	1.38	1.90
Recurring cash flow per share	1.80	`1.79	1.85	2.10	2.36
Balance Sheet (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Tangible fixed assets (gross)	498	1,242	1,578	1,665	1,740
Less: Accumulated depreciation	(73)	(339)	(366)	(395)	(427)
Tangible fixed assets (net)	424	903	1,211	1,270	1,313
Intangible fixed assets (net)	7	7	7	7	7
Long-term financial assets Invest. in associates & subsidiaries	8	15 362	15 1,799	15 1,953	15 1,992
Cash & equivalents	98	627	341	512	802
A/C receivable	5	7	6	7	8
Inventories	63	101	101	110	123
Other current assets	166	1,136	292	272	304
Current assets	331	1,871	740	901	1,236
Other assets	177	480	225	247	277
Total assets Common equity	947 404	3,637 2,991	3,997 3,394	4,392 3,761	4,840 4,184
Minorities etc.	0	0	0	0	0
Total shareholders' equity	404	2,991	3,394	3,761	4,184
Long term debt	291	294	292	291	289
Other long-term liabilities	3	5	4	5	6
Long-term liabilities	294	298	297	296	295
A/C payable Short term debt	148 15	260 2	204 2	223 2	249 2
Other current liabilities	86	86	101	111	111
Current liabilities	249	348	306	335	361
Total liabilities and shareholders' equity	947	3,637	3,997	4,392	4,840
Net working capital	0	898	95	55	75
Invested capital	616	2,664	3,352	3,546	3,678
* Includes convertibles and preferred stock which is being	ig treated as debt				
Per share (THB)	2.42	44.22	44.0F	10.47	12.07
Book value per share Tangible book value per share	2.12 2.09	11.33 11.30	11.25 11.23	12.47 12.44	13.87 13.85
Financial strength	2.03	11.50	11.20	14.77	10.00
Net debt/equity (%)	51.7	(11.1)	(1.4)	(5.8)	(12.2)
Net debt/total assets (%)	22.1	(9.1)	(1.2)	(5.0)	(10.6)
Current ratio (x)	1.3	5.4	2.4	2.7	3.4
CF interest cover (x)	105.2	64.0	55.4	70.7	79.0
Valuation	2022	2023	2024E	2025E	2026E
Recurring P/E (x) *	25.3	25.8	23.4	20.1	17.4
Recurring P/E @ target price (x) *	32.3	33.0	29.9	25.7	22.3
Reported P/E (x) Dividend yield (%)	25.3 0.7	25.8 0.7	23.4 1.3	20.1 2.0	17.4 2.3
Price/book (x)	19.2	3.6	3.6	3.3	2.3 2.9
Price/tangible book (x)	19.5	3.6	3.6	3.3	2.9
EV/EBITDA (x) **	18.9	17.8	18.0	15.6	13.5
EV/EBITDA @ target price (x) **	23.9	22.8	23.0	19.9	17.3
EV/invested capital (x)	12.9	3.9	3.7	3.4	3.2
* Pre-exceptional, pre-goodwill and fully diluted ** EB	ITDA includes associate	e income and recur	ring non-operating ir	ncome	

Sources: Master Style; FSSIA estimates

Disclaimer for ESG scoring

ESG score	Methodolog	у			Rating					
The Dow Jones Sustainability Indices (<u>DJSI</u>) By S&P Global	process bas from the ann	ed on the com	transparent, rules-based npanies' Total Sustainabil al Corporate Sustainabili anies within each industr	lity Scores resulting ity Assessment (CSA).	Sustainability Assessment (CSA) for DJSI. Companies with an S&P Glo					
Sustainability Investment List (THSI) by (THS Stock Exchange of Thailand (SET)	managing be Candidates 1) no irregul float of >150 up capital. S 70%; 2) inde wrongdoing	usiness with tra must pass the lar trading of the shareholders. Some key disque ependent direct related to CG,	ility in Environmental and cansparency in Governan preemptive criteria, with the board members and e. s, and combined holding re ualifying criteria include: ctors and free float violation, social & environmental in carnings in red for > 3 years	ce, updated annually. two crucial conditions: xecutives; and 2) free must be >15% of paid- 1) CG score of below on; 3) executives' impacts; 4) equity in	nature of the relevant industry and materiality.					
CG Score by Thai Institute of Directors Association (Thai IOD)	annually by Thailand (St	the Thai IOD,	h in sustainable developr with support from the Stc ts are from the perspectiv s.	ock Exchange of	Good (80-89), 3 and not rated for equitable treatr	3 for Good (70 or scores belo nent of shareh 25%); 4) disclo	ories: 5 for Excel 0-79), 2 for Fair (6 w 50. Weightings nolders (weight 2 sure & transpare	60-69), 1 for P s include: 1) th 5% combined	ass (60-69), le rights; 2) an); 3) the role of	
AGM level By Thai Investors Association (TIA) with support from the SEC	treatment ar transparent out of five th criteria cove date (45%), circulation of s exercised. The and verifiability	It quantifies the extent to which shareholders' rights and equitable treatment are incorporated into business operations and information is transparent and sufficiently disclosed. All form important elements of two out of five the CG components to be evaluated annually. The assessment criteria cover AGM procedures before the meeting (45%), at the meeting date (45%), and after the meeting (10%). (The first assesses 1) advance circulation of sufficient information for voting; and 2) facilitating how voting rights can be exercised. The second assesses 1) the ease of attending meetings; 2) transparency and verifiability; and 3) openness for Q&A. The third involves the meeting minutes that should contain discussion issues, resolutions and voting results.)								
Thai CAC By Thai Private Sector Collective Action Against Corruption (CAC)	establishme policies. The (Companies of Declaration of Certification, in managers and	ent of key contrible Certification in leciding to become function to kick off Intent to kick off Including risk asso	Checklist include corrupti rols, and the monitoring a is good for three years. he a CAC certified member si an 18-month deadline to sub- tessment, in place of policy at ablishment of whistleblowing Il stakeholders.)	The document will be reviewed by a committee of nine professionals. A passed Checklist will move for granting certification by the CAC Counc approvals whose members are twelve highly respected individuals in professionalism and ethical achievements.						
Morningstar Sustainalytics	based on an risk is unma	n assessment of naged. Sources	sk rating provides an ove of how much of a compar s to be reviewed include corp her media, NGO reports/webs	more risk is uni	managed, the	score is the sum higher ESG risk	is scored.			
		ompany feedbaci Juality & peer revi	k, ESG controversies, issuer iews.	feedback on draft ESG	NEGL 0-10	Low 10-20	Medium 20-30	High 30-40	Severe 40+	
ESG Book	positioned to the principle helps explai over-weighti	o outperform o of financial mandial manuscription of the order of the outperform of	sustainable companies the long term. The materiality including inform djusted performance. Matth higher materiality and erly basis.	ethodology considers eation that significantly teriality is applied by	cantly and 100 with higher scores indicating better performance. d by					
MSCI				anagement of financially in their exposure to ESG ris					nethodology to	
	AAA	8.571-10.000	0 London	La andre en tra de alemane de casa			-1	_		
	AA	7.143-8.570	Leader:	leading its industry in ma	anaging the most si	gnilicant ESG fi	sks and opportunitie	38		
	Α	5.714-7.142	2	a material and the second	al tarada a di d			alaa aa d	internal Control	
	BBB	4.286-5.713	Average:	a mixed or unexceptional industry peers	al track record of ma	anaging the mos	si significant ESG ris	sks and opportu	illes relative to	
	ВВ	2.857-4.285	;							
	В	1.429-2.856	Laggard:	lagging its industry base	ed on its high expos	ure and failure t	o manage significar	nt ESG risks		
	ccc	0.000-1.428	}							
Moody's ESG colutions	believes tha	t a company in		take into account ESG of to its business model and medium to long term.						
Refinitiv ESG rating	based on pu	ublicly available	e and auditable data. The	a company's relative ESG e score ranges from 0 to a e 0 to 25 = poor; >25 to 50 =	100 on relative E	SG performar	nce and insufficie	nt degree of t		
S&P Global							of ESG risks, op	portunities, an	d impacts	
Bloomberg	The S&P Global ESG Score is a relative score measuring a company's performance on and management of ESG risks, opportunities, and impacts compared to its peers within the same industry classification. The score ranges from 0 to 100. ESG Score Bloomberg score evaluating the company's aggregated Environmental, Social and Governance (ESG) performance. The score is based on Bloomberg's view of ESG financial materiality. The score is a weighted generalized mean (power mean)								power mean)	
			of Pillar Scores, where	the weights are determin	ed by the pillar p	riority ranking	. Values larige ili	om 0 to 10; 10	is the best.	

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings.

Source: FSSIA's compilation

GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION

Sureeporn Teewasuwet FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

History of change in investment rating and/or target price



27-Feb-2024

Sureeporn Teewasuwet started covering this stock from 12-Dec-2023

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Master Style	MASTER TB	THB 40.75	BUY	Downside risks to our P/E-based TP include 1) increased competition, 2) a pandemic that results in a lockdown, 3) lower-than-expected utilization rate of new operating beds, 4) higher-than-expected doctor costs and expenses, and 5) a loss contribution from the acquired units.

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 15-Aug-2024 unless otherwise stated.

RECOMMENDATION STRUCTURE

Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Industry Recommendations

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months.

Neutral. The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months.

Underweight. The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

Country (Strategy) Recommendations

Overweight (O). Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.